Monotherapy with low-dose thalidomide for relapsed or refractory multiple myeloma: better response rate with earlier treatment

MAISNAR, Vladimír, J. RADOCHA, Tomáš BÜCHLER, V. BLÁHA, J. MALÝ and Roman HÁJEK. Monotherapy with low-dose thalidomide for relapsed or refractory multiple myeloma: better response rate with earlier treatment. European Journal of Haematology. England: Blackwell, 2007, vol. 79, No 4, p. 305-309. ISSN 0902-4441.

Basic information

Original name

Monotherapy with low-dose thalidomide for relapsed or refractory multiple myeloma: better response rate with earlier treatment

Name in Czech

Monoterapie nízkodávkovaným thalidomidem pro relabovaný a refrakterní mnohočetný myelom: s časnější léčboul epší léčebná odpověď

Authors

MAISNAR, Vladimír (203 Czech Republic), J. RADOCHA (203 Czech Republic), Tomáš BÜCHLER (203 Czech Republic), V. BLÁHA (203 Czech Republic), J. MALÝ (203 Czech Republic) and Roman HÁJEK (203 Czech Republic, guarantor)

Edition

European Journal of Haematology, England, Blackwell, 2007, 0902-4441

---

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

30200 3.2 Clinical medicine

Country of publisher

United Kingdom of Great Britain and Northern Ireland

Confidentiality degree

není předmětem státního či obchodního tajemství

Impact factor

Impact factor: 2.163

RIV identification code

RIV/00216224:14110/07:00035883

Organization unit

Faculty of Medicine

UT WoS

000249428100006

Keywords (in Czech)

mnohočetný myelom;thalidomid;monoterapie

Keywords in English

thalidomide; monotherapy; multiple myeloma; treatment; relapse

Tags

monotherapy, multiple myeloma, relapse, Thalidomide, treatment

Tags

International impact, Reviewed

---

Abstract

V originále

Thalidomide is an immunomodulatory drug used in the treatment of relapsed or refractory multiple myeloma (MM). The optimal dosing regimen of thalidomide is not known. Patients and Methods: We retrospectively analysed the overall response rate and response duration of 53 patients with relapsed MM who received thalidomide in a median dose of 100 mg daily. The aim of the study was to compare the response rates of thalidomide given as the second-line treatment to those of thalidomide given as the third-line therapy.

In Czech

Thalidomid je imunomodulační látka používaná při léčbě refrakterního mnohočetného myelomu. V publikaci je popsána léčba 53 pacientů s MM. Cílem studie bylo porovnat léčebné odpovědi pacientů, kteří dostali thalidomid ve druhé linii léčby a třetí linii léčby.